法》《上市公司收购管理办法》《公开发行证券公司信息披露内容与格式准则第 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在福建万辰生物科技集团股份有限公司（以下 简称"万辰集团"或"上市公司"）拥有权益的股份变动情况。截至本报告书签署之 日，除本报告书披露的信息外，信息披露义务人没有通过任何其他方式增加或减 少其在上市公司拥有权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的。除本信息披露义务人 外，没有委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书 做出任何解释或者说明。 五、信息披露义务人承诺本报告不存在虚假记载、误导性陈述或重大遗漏， 并对其真实性、准确性和完整性承担个别和连带的法律责任。 福建万辰生物科技集团股份有限公司 上市公司名称：福建万辰生物科技集团股份有限公司 股票上市地点：深圳证券交易所 股票简称：万辰集团 股票代码：300972 信息披露义务人一：福建含羞草农业开发有限公司 住所：福建 ...

Core Viewpoint - The financial advisor, Everbright Securities, has conducted a thorough review of the equity change report for Southern Black Sesame Group Co., Ltd, confirming the authenticity, accuracy, and completeness of the disclosed information, and asserting that the equity change aims to enhance the company's management and resource allocation, ultimately improving profitability and market competitiveness [1][5][6]. Summary by Sections 1. Authenticity, Accuracy, and Completeness of Information - The financial advisor has verified that the information provided in the detailed equity change report is true, accurate, and complete, in compliance with relevant laws and regulations [5][6]. - The advisor has not found any false records, misleading statements, or significant omissions in the report [5][6]. 2. Purpose of the Equity Change - The equity change is aimed at gaining control over the listed company, with the intention of leveraging industry resources and management expertise to enhance business development and shareholder returns [6][12]. 3. Future Plans of the Information Disclosure Obligor - There are currently no specific plans for further share increases or disposals within the next 12 months, and any future changes will be disclosed in accordance with legal requirements [6][12]. - The information disclosure obligor supports the stable development of the company's existing business and does not plan any major adjustments to the main business in the next 12 months [17][18]. 4. Financial Status and Business Operations - The information disclosure obligor, Guangxi Travel Health Industry Group Co., Ltd, focuses on three main business sectors: medical services, elderly care, and health food, aiming to become a leader in the regional health industry [12][13]. - Recent financial data indicates a total asset increase from 484,254.56 million yuan in 2023 to 604,096.11 million yuan in 2024, with a net profit of 7,161.21 million yuan in 2024 [13]. 5. Impact on the Listed Company - The equity change will not affect the independence of the listed company, which will maintain its independent legal status and governance structure [22][23]. - The financial advisor has confirmed that there are no substantial competitive overlaps between the businesses of the information disclosure obligor and the listed company, ensuring no significant competition arises from this equity change [22][23]. 6. Compliance and Governance - The information disclosure obligor has adhered to necessary internal approval processes for the equity change, including board meetings and approvals from relevant authorities [17][19]. - The advisor has provided guidance to ensure compliance with market regulations and will oversee the information disclosure obligations related to the equity change [15].

深圳市致尚科技股份有限公司 简式权益变动报告书 深圳市致尚科技股份有限公司 上市公司名称：深圳市致尚科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：致尚科技 股票代码：301486 信息披露义务人一：李浩 住所及通讯地址：深圳市南山区**** 信息披露义务人二：深圳市海纳天勤投资有限公司 住所及通讯地址：深圳市南山区东滨路华联城市山林花园二期 7 栋 14-24D 信息披露义务人三：深圳市恒永诚投资合伙企业（有限合伙） 住所及通讯地址：深圳市南山区粤海街道滨海社区海天二路 14 号软件产业基地 信息披露义务人四：深圳市恒永信企业管理合伙企业（有限合伙） 住所及通讯地址：深圳市南山区粤海街道滨海社区海天一路 11、13、15 号深圳 市软件产业基地 5 栋 D702 权益变动性质：增持（以资产及现金认购上市公司发行股份） 签署日期：2025 年 8 月 11 日 深圳市致尚科技股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》 （以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司收购管理办 《公开发行证券的公司信息披 ...

二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在安徽丰原药业股份有限公司拥有权益的 股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述信息披 露义务人没有通过任何其他方式增加或减少其在安徽丰原药业股份有限公司中 拥有权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的。除本信息披露义务人 外，没有委托或者授权其它任何人提供未在本报告书列载的信息和对本报告书做 出任何解释或者说明。 五、本次权益变动尚需按照深圳证券交易所协议转让相关规定履行合规性 确认等程序，并在中国证券登记结算有限责任公司深圳分公司办理股份过户登记 手续。 安徽丰原药业股份有限公司 简式权益变动报告书 上市公司名称：安徽丰原药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：丰原药业 股票代码：000153 信息披露义务人一：安徽丰原集团有限公司 住所：安徽省蚌埠市禹会区胜利西路777号 通讯地址：安徽省蚌埠市禹会区胜利西路777号 信 ...

Core Viewpoint - The report details the equity change of Zhejiang Weixing Intelligent Instrument Co., Ltd., specifically the reduction of shareholding by the information disclosure obligor, Huang Wenqian, due to personal funding needs [1][4]. Group 1: Equity Change Details - Huang Wenqian reduced his shareholding from 33,706,830 shares (15.28% of total shares) to 33,095,130 shares (15.00% of total shares) [5][11]. - The total number of shares reduced was 611,700, which accounts for 0.2772% of the company's total shares [6][11]. - The reduction was executed through centralized bidding, with an average selling price of 16.04 yuan per share for 581,700 shares and 15.85 yuan per share for 30,000 shares [7][11]. Group 2: Future Plans and Compliance - Huang Wenqian plans to continue reducing his shareholding by up to 4,400,000 shares (1.99% of total shares) within three months following the announcement of the reduction plan [4][5]. - The report confirms that Huang Wenqian has not engaged in any trading of Weixing Intelligent shares in the six months prior to the report [6][12]. - The information disclosure obligor has committed to comply with relevant laws and regulations regarding the disclosure of information [2][8].

安正时尚集团股份有限公司 简式权益变动报告书（一） 上市公司名称：安正时尚集团股份有限公司 上市地点：上海证券交易所 股票简称：安正时尚 股票代码：603839 信息披露义务人信息： 信息披露义务人：上海阿杏投资管理有限公司（代表"阿杏海洋星 1 号私募证券 投资基金"）（以下简称"阿杏海洋星 1 号基金"） 住所/通讯地址：上海市浦东新区民生路 1518 号含笑路 80 号金鹰大厦 A 楼 1104A 室 权益变动性质：协议转让，股份减少 一致行动人：郑安政 住所/通讯地址：浙江省嘉兴市海宁市*** 一致行动人：陈克川 住所/通讯地址：浙江省嘉兴市海宁市*** 一致行动人：郑安坤 住所/通讯地址：浙江省嘉兴市海宁市*** 一致行动人：郑安杰 住所/通讯地址：浙江省嘉兴市海宁市*** 一致行动人：郑秀萍 住所/通讯地址：浙江省嘉兴市海宁市*** 一致行动人： 金素芬（金素芬为财通证券资管－金素芬－财通证券资管智汇 99 号单一资产管理计划（以下简称"财通资管计划"）唯一受益人，其与郑安政为 夫妻关系） 住所/通讯地址：浙江省嘉兴市海宁市*** 签署日期：2025 年 8 月 10 日 信息披露义务人申明 《公 ...

Group 1 - The core point of the announcement is that the controlling shareholder and its concerted parties have experienced a change in equity that has reached the 1% threshold due to the cancellation of restricted stock [2][3] - The controlling shareholder, Hongdou Group, and its concerted parties' shareholding increased from 1,444,184,395 shares (62.88%) to 1,445,060,999 shares (63.07%) following the cancellation of 5,200,000 restricted shares [2][3] - The total share capital of the company decreased from 2,296,571,852 shares to 2,291,371,852 shares after the cancellation of the restricted stock [2][3] Group 2 - The change in equity is a result of the company's decision to terminate the 2021 restricted stock incentive plan and the subsequent cancellation of related restricted stocks [2][3] - This equity change does not trigger a mandatory tender offer and will not lead to a change in the controlling shareholder or actual controller of the company [3] - The announcement confirms that the information provided by the controlling shareholder and its concerted parties is accurate and complete [1][4]

Core Viewpoint - The announcement details a change in the equity structure of Hongdou Group and its concerted actions, indicating an increase in their shareholding percentage from 62.88% to 63.07% [1][3]. Group 1: Equity Change Details - The equity change direction is an increase, with the total shareholding percentage rising from 62.88% to 63.07% [1]. - The change does not violate any prior commitments or plans, and it does not trigger mandatory tender offer obligations [1]. - The number of shares held by the controlling shareholder and its concerted actions increased, with specific individuals' holdings detailed [3]. Group 2: Shareholder Information - The controlling shareholder is Hongdou Group Co., Ltd., with key individuals including Zhou Haijiang, Gong Xindu, and Wang Zhuqian listed as concerted actions [1][3]. - Zhou Haijiang's shareholding increased from 4,796.3491 thousand shares (2.09%) to 5,806.3491 thousand shares (2.53%) [3]. - The total number of shares held by the group increased from 144,418.4395 thousand shares (62.88%) to 144,506.0999 thousand shares (63.07%) [3]. Group 3: Stock Incentive Plan - The company terminated the implementation of the 2021 restricted stock incentive plan and completed the cancellation of 5,200,000 shares of restricted stock [2]. - Following the cancellation, the total share capital changed from 2,296,571,852 shares to a new total [2].

Group 1 - The core point of the report is that Hunan Sailoxian Management Consulting Partnership (Limited Partnership) has acquired 58,606,962 shares of Qidi Pharmaceutical Group Co., Ltd., representing 24.47% of the total shares, through judicial auction, making it the controlling shareholder of the company [1][18][24] - The acquisition was executed following a court ruling and was completed on August 5, 2025, with the total payment amounting to 1,007.39 million yuan [20][19] - The report confirms that the acquisition does not aim to terminate the listing status of Qidi Pharmaceutical and that the company will continue to operate independently [17][23] Group 2 - Hunan Sailoxian was established on June 19, 2025, primarily engaged in investment management, with a registered capital of 405.57 million yuan [4][6] - The actual controller of Hunan Sailoxian is Jiang Lin, who holds 66.86% of the shares in the executing partner, Shanghai Sailoxian [5][6] - Qidi Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on the research and development of traditional Chinese medicine and Western medicine formulations, with over 140 drug varieties and more than 30 patents [24][25] Group 3 - The financial data of Shanghai Sailoxian shows total assets of 1,650.71 million yuan and total equity of 1,322.98 million yuan as of December 31, 2024, with a net profit of 93.54 million yuan [6][13] - The report indicates that there are no significant legal violations or administrative penalties against Hunan Sailoxian in the past five years [14][16] - The report outlines that there is a potential for competition between Qidi Pharmaceutical and Hunan Sailoxian's core enterprise, Hengchang Pharmaceutical, due to overlapping product lines [24][26]

Core Viewpoint - The report details the equity change of Citic Prudential Life Insurance Co., Ltd. in Canar Technology Co., Ltd., indicating a reduction in shareholding below 5% [1][2]. Group 1: Equity Change Details - Citic Prudential Life Insurance reduced its shareholding from 7,146,348 shares (5.8459%) to 6,112,253 shares (4.99998%) [8]. - The reduction involved selling 1,034,095 shares, which represents a decrease of 0.8459% in the total shareholding [8]. - The shares were sold through centralized bidding from July 30, 2025, to August 6, 2025 [9]. Group 2: Future Plans - Citic Prudential Life Insurance plans to continue reducing its holdings, with a maximum of 3,667,300 shares (up to 3% of the total share capital) to be sold within three months following the announcement made on April 24, 2025 [6][7]. - There are no plans for increasing shareholding in the next 12 months [6]. Group 3: Compliance and Disclosure - The report confirms that all necessary authorizations and approvals for the equity change have been obtained, ensuring compliance with relevant laws and regulations [1][2]. - Citic Prudential Life Insurance has committed to the accuracy and completeness of the report, taking legal responsibility for any misrepresentation [2][10].